Literature DB >> 12835707

Twenty years of therapy for HIV-1 infection.

Roger J Pomerantz1, David L Horn.   

Abstract

Antiretroviral therapy, where available, has transformed HIV-1 disease into a treatable and somewhat chronic infection. This article summarizes the accomplishments thus far and what lies ahead in our struggle to improve the treatment of, and possibly eliminate, HIV-1 infection.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12835707     DOI： 10.1038/nm0703-867

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


  61 in total

1.  Potent antiviral HIV-1 protease inhibitor GRL-02031 adapts to the structures of drug resistant mutants with its P1'-pyrrolidinone ring.

Authors:  Yu-Chung E Chang; XiaXia Yu; Ying Zhang; Yunfeng Tie; Yuan-Fang Wang; Sofiya Yashchuk; Arun K Ghosh; Robert W Harrison; Irene T Weber
Journal:  J Med Chem       Date:  2012-03-22       Impact factor: 7.446

2.  Blocking the docking of HIV-1.

Authors:  Aine McKnight; Robin A Weiss
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-08       Impact factor: 11.205

3.  Protein conformational dynamics in the mechanism of HIV-1 protease catalysis.

Authors:  Vladimir Yu Torbeev; H Raghuraman; Donald Hamelberg; Marco Tonelli; William M Westler; Eduardo Perozo; Stephen B H Kent
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-08       Impact factor: 11.205

Review 4.  The impact of disease stage on direct medical costs of HIV management: a review of the international literature.

Authors:  Adrian Levy; Karissa Johnston; Lieven Annemans; Andrea Tramarin; Julio Montaner
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

5.  Modelling the budget impact of darunavir in the treatment of highly treatment-experienced, HIV-infected adults in France.

Authors:  Xavier Colin; Antoine Lafuma; Dominique Costagliola; Erik Smets; Josephine Mauskopf; Pascal Guillon
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

6.  Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK.

Authors:  Karen Moeremans; Lieven Annemans; Mickael Löthgren; Gabriele Allegri; Veronique Wyffels; Lindsay Hemmet; Karin Caekelbergh; Erik Smets
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 7.  Clinical management of treatment-experienced, HIV/AIDS patients in the combination antiretroviral therapy era.

Authors:  Mark A Boyd; Andrew M Hill
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

8.  Development of a new methodology for screening of human immunodeficiency virus type 1 microbicides based on real-time PCR quantification.

Authors:  Renato S Aguiar; Luciana J Costa; Helena S Pereira; Rodrigo M Brindeiro; Amilcar Tanuri
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

9.  Galectin-1-specific inhibitors as a new class of compounds to treat HIV-1 infection.

Authors:  Christian St-Pierre; Michel Ouellet; Denis Giguère; Reiko Ohtake; René Roy; Sachiko Sato; Michel J Tremblay
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

10.  Structure-based evaluation of C5 derivatives in the catechol diether series targeting HIV-1 reverse transcriptase.

Authors:  Kathleen M Frey; William T Gray; Krasimir A Spasov; Mariela Bollini; Ricardo Gallardo-Macias; William L Jorgensen; Karen S Anderson
Journal:  Chem Biol Drug Des       Date:  2014-03-14       Impact factor: 2.817
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.